Loading...
01/10 16:34
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed picture: strong financial performance with record high revenue and improved profitability, but concerns about cash reduction and uncertain guidance. The Q&A indicates solid demand and growth prospects, but management's lack of specific guidance and avoidance of details raises uncertainty. Without clear guidance, the market may react cautiously, resulting in a neutral stock price movement.
Fourth Quarter Revenue $229 million, up 11% year-over-year, driven by strong demand from global CT customers and strength in the Industrial segment.
Industrial Segment Revenue (Q4) $77 million, the highest revenue quarter ever for this segment, up 25% year-over-year, driven by demand for security inspection systems and components.
Medical Segment Revenue (Q4) $152 million, up 5% year-over-year, led by global sales of CT tubes and strong performance in fluoroscopy and radiography.
Non-GAAP Gross Margin (Q4) 34%, up 130 basis points year-over-year, benefiting from higher volume and favorable product sales mix.
Non-GAAP Earnings Per Share (Q4) $0.37, up $0.21 compared to last year, reflecting improved operational performance.
Full Fiscal Year Revenue $845 million, up 4% year-over-year, with Medical revenue at $593 million (up 2%) and Industrial revenue at $252 million (up 10%).
Non-GAAP Gross Margin (Full Year) 35%, up 230 basis points year-over-year, driven by operational improvements and favorable sales mix.
Non-GAAP EBITDA (Full Year) $122 million, up $33 million from $89 million last year, reflecting strong financial performance.
Non-GAAP Earnings Per Share (Full Year) $0.90, up $0.35 year-over-year, indicating improved profitability.
Cash, Cash Equivalents, and Marketable Securities (End of Year) $155 million, down from $213 million last year, primarily due to $75 million used to retire convertible debt.
Operating Income (Q4) $20 million, an increase of $9 million compared to the previous year, with an operating margin of 10% of revenue.
Net Income (Q4) $12 million, with GAAP EPS of $0.29 per share, reflecting improved financial results.
Adjusted EBITDA (Q4) $35 million, representing 15% of sales, showcasing strong quarterly performance.
R&D Spending (Q4) $24 million, up $2 million year-over-year, representing 10% of revenues, driven by investments in growth initiatives.
SG&A Expense (Full Year) $122 million, down $1 million year-over-year, representing 14% of revenues, indicating cost management.
Photon Counting for CT: Introduced innovative photon counting technology for CT, collaborating with OEM customers and the Technical University of Munich to advance product development.
Radiographic Detector for Value Segment: Launched a radiographic detector from a new facility in India, targeting the value segment.
Cargo Systems in Industrial: Developed and shipped over 15 cargo inspection systems to countries like Mexico, Iraq, Brazil, and Saudi Arabia, with $55 million in orders booked.
Geographic Expansion: Expanded sales in regions like India, South Asia, the Middle East, and Latin America, focusing on value and mid-tier products for radiographic and CT systems.
China Market Recovery: Observed increased tender activity in China, driven by rural healthcare expansion plans and demand for value and mid-tier CT systems.
India Facility Expansion: Completed the first stage of India expansion plans, ramping up production of radiographic detectors and enabling vertical integration for cost reduction.
Supply Chain Regionalization: Strengthened geopolitical resiliency through regionalized supply chains and export-oriented manufacturing.
Photon Counting CT Demonstrator: Collaborated with the Technical University of Munich to develop a photon counting CT system demonstrator, showcasing its value proposition at trade shows in 2026.
Nanotube-Based Coal Emitters: Invested in nanotube-based coal emitters for next-generation X-ray sources, collaborating with OEMs to develop novel applications.
Global Tariff Challenges: The company faced a challenging start to fiscal 2025 due to unpredictable global tariff situations, which impacted customer ordering patterns. Although the situation stabilized, it remains a potential risk for future operations.
China Market Uncertainty: Uncertainty around the implementation of stimulus programs in China led to delays in imaging equipment purchases. While this appears to be resolved, it highlights the risk of dependency on specific markets.
Supply Chain and Manufacturing Regionalization: The company is intensifying efforts to strengthen geopolitical resiliency through supply chain and manufacturing regionalization. This indicates potential risks related to supply chain disruptions and trade challenges.
Debt Levels: The company used $75 million to retire convertible debt, reducing cash reserves from $213 million to $155 million. This could limit financial flexibility for future investments or operations.
Photon Counting CT Development: While progress has been made, the adoption of photon counting CT technology is still in early stages and depends on securing additional OEM design-ins, which poses a strategic execution risk.
Nanotube-Based Coal Emitters: The development of nanotube-based coal emitters is in collaboration with OEMs, but bringing applications to market takes time, posing a risk of delayed returns on investment.
Industrial Segment Scaling: Scaling up production capacity for cargo systems in fiscal 2026 involves operational risks, including meeting demand and maintaining quality standards.
R&D Investment: Increased R&D spending, particularly in growth initiatives like photon counting and security systems, represents a financial risk if these investments do not yield expected returns.
Revenue Expectations: Revenues for the first quarter of fiscal 2026 are expected to be between $200 million and $215 million.
Earnings Per Share (EPS): Non-GAAP earnings per diluted share for the first quarter of fiscal 2026 are expected to range between $0.05 and $0.25.
Gross Margin: Non-GAAP gross margin for the first quarter of fiscal 2026 is projected to be between 32% and 34%.
Operating Expenses: Non-GAAP operating expenses for the first quarter of fiscal 2026 are expected to be approximately $52 million.
Tax Rate: The tax rate for the first quarter of fiscal 2026 is expected to be about 23%.
Photon Counting CT: Plans to showcase a photon counting CT system at major trade shows in 2026, aiming to demonstrate its value proposition beyond higher resolution images, including precise material discrimination and improved workflow.
India Expansion: The detectors factory in Vizag, India is ramping up production of radiographic detectors, with plans for further vertical integration to support cost-reduction efforts.
Cargo Systems: Scaling up production capacity of cargo systems in fiscal 2026, including implementing a rail cargo scanner in Latin America and leveraging strong customer relationships for upcoming tenders.
Nanotube Technology: Continued investment in nanotube-based coal emitters, with plans to provide more visibility to this technology at trade shows in fiscal 2026.
China Market Recovery: Customers in China are projecting stronger orders and sales for 2026 compared to 2024 and 2025, driven by increased tender activity for value and mid-tier CT systems to support rural healthcare expansion plans.
The selected topic was not discussed during the call.
The earnings call presents a mixed picture: strong financial performance with record high revenue and improved profitability, but concerns about cash reduction and uncertain guidance. The Q&A indicates solid demand and growth prospects, but management's lack of specific guidance and avoidance of details raises uncertainty. Without clear guidance, the market may react cautiously, resulting in a neutral stock price movement.
The earnings call summary presents a mixed picture. Financial performance is stable with strong cash management and expected revenue growth, but gross margins are impacted by tariffs. Product development in photon counting is promising but lacks immediate commercialization. Market strategy shows steady demand in China and a strong cargo systems pipeline, but lacks clarity in future guidance. Shareholder returns and debt repayment plans are positive, yet overall, the lack of clear guidance and tariff impacts balance the sentiment to neutral.
The earnings call summary presents mixed signals: strong financial results with revenue and EPS growth, but concerns over China tariffs and paused orders. The Q&A reveals management's uncertainty about the tariff impact and delayed orders, but they express confidence in temporary revenue reductions. The strategic plan highlights a significant cargo inspection order and growth opportunities, yet geopolitical risks loom. Overall, the positive financial performance is offset by uncertainties in China, leading to a neutral stock price prediction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
